%0 Journal Article
%T Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction.
%A Wang Y
%A Branco RF
%A Salanitro M
%A Penzel T
%A Schöbel C
%J Sleep Breath
%V 27
%N 1
%D 03 2023
%M 35486312
%F 2.655
%R 10.1007/s11325-022-02623-0
%X This study aimed to evaluate the effect of sacubitril-valsartan (SV) on central apneas (CA) and obstructive apneas (OA) in patients with heart failure with reduced ejection fraction (HFrEF).
In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.
Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05).
In this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.